KRAS status and survival in multicenter study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment.

Meaghan Dendy Case,Anish Ghodadra,Paula M. Novelli,Vincent Wu,Suvranu Ganguli,Moritz Wildgruber,Michael Köhler,Charles Robinson,Charles Y. Kim,David S. Wang,Daniel Y. Sze,Kenneth J. Kolbeck,Lori Russell,Johannes Uhlig,Johannes M. Ludwig,Hyun S. Kim

KRAS status and survival in multicenter study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment.

2020

Meaghan Dendy Case
Anish Ghodadra
Paula M. Novelli
Vincent Wu
Suvranu Ganguli
Moritz Wildgruber
Michael Köhler
Charles Robinson
Charles Y. Kim
David S. Wang
Daniel Y. Sze
Kenneth J. Kolbeck
Lori Russell
Johannes Uhlig
Johannes M. Ludwig
Hyun S. Kim

239Background: Assessment of the clinical outcome and prognostic factors of patients receiving Y90 radioembolization to treat colorectal liver metastases. Methods: Multi-institution retrospective s...

Keywords:

KRAS
Internal medicine
multicenter study
Oncology
Medicine
Pathology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations